Nektar Therapeutics (0UNL.L) LSE

57.64

+2.8026(+5.11%)

Updated at December 04 07:00PM

Currency In USD

Valuation

Market Cap191.26M
Enterprise Value249.58M
P/E Ratio-9.05
PEG Ratio-1
Price/Sales Ratio18.75
Price/Book Ratio12.85
Enterprise/Revenue19.56
Enterprise/EBITDA-13.77

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterSeptember 30, 2025

Profitability

Profit Margin-1.93
Operating Margin-1.57

Management Effectiveness

Return On Assets-0.4
Return On Equity-3.57

Income Statement

Revenue98.43M
Revenue/Share3.3
Gross Profit67.74M
EBITDA-86.7M
Net Income-118.96M
Diluted EPS-8.68

Balance Sheet

Total Cash270.21M
Total Cash/Share14.26
Total Debt91.92M
Total Debt/Equity1.08
Current Ratio4.24
Book Value Per Share4.49

Price History

52-Week Change5,496.13
52-Week High57.66
52-Week Low55
Moving Average 50 Days38.02
Moving Average 200 Days33.28

Statistics

Average Volume10,748.65
Shares Outstanding20.34M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A